Merck Wins Summary Judgment involving Fosamax (alendronate sodium)

The U.S. District Court Judge John F. Keenan granted summary judgment in Merck's favor in Flemings v. Merck.Flemings is the second of three cases involving FOSAMAX (alendronate sodium) designated by the federal MDL court as a bellwether trial case. In granting summary judgment in Flemings and dismissing all of the plaintiff's claims, Judge Keenan ruled that the physician relied upon by Ms. Flemings (Dr. Rose) was unqualified to render an opinion and that Ms. Flemings failed to present sufficient evidence to support her contention that FOSAMAX caused her to sustain osteonecrosis of the jaw (ONJ).

USFDA grants tentative approval to Sun Pharma's generic version of Gleevec® tablets

The USFDA has granted tentative approval Sun Pharma's ANDA for generic Gleevec®, imatinib mesylate tablets. These imatinib mesylate tablets, therapeutically equivalent to Gleevec® tablets from Novartis, have two strengths viz. 100 mg and 400 mg and have annual sales of approximately USD 950 million in the US.Imatinib mesylate is used for patients with chronic myeloid leukemia. Gleevec® is a registered trademark of Novartis.

IP Blogger is back

Dear Friends,

It's been a long break from mu usual routine of blogging. IP has developed so much in the recent times that even a small contribution would be like a pebble in the ocean.

But still, i will try my level best to keep upbreast with the knowledge.

Regards,

IP Blogger